ARTICLES LIST

 

Total Results: 16203

Media ID Source Name Media Type Language Media Name Media Description Keywords Keywords Link to Article
1339 National Cancer Institute Html en "Light" Cigarettes and Cancer Risk This fact sheet answers questions about the health effects of smoking
tar yield ratings0.57737
Tobacco Control Act0.536069
[PubMed Abstract]0.48947
lung cancer0.486686
cigarette engineering0.5215
cancer prevention study0.484602
full-flavor cigarettes0.614325
tobacco0.630562
tobacco manufacturers0.618735
Tobacco Control Monograph0.517669
light cigarette0.806133
tar0.70637
color-coded packaging0.502935
tobacco industry0.590796
silver packaging0.501078
tobacco products0.527514
Family Smoking Prevention0.526471
President Barack Obama0.486716
cigarette package design0.557863
Smoking Cigarettes0.586945
previously marketed products0.585107
full-flavor cigarette0.528959
so-called light cigarette0.757572
regular cigarettes0.701052
acute myeloid leukemia0.482821
safe cigarette0.580948
National Cancer Institute0.624018
smoking machine0.528809
greater tar exposure0.608329
machine-measured tar yields0.568171
light cigarettes0.927757
lower yield0.510032
Cigarette features0.526777
frequent puffs0.539497
USA. Tobacco Control0.516673
Cigarette tar yields0.63309
Federal Trade Commission0.480817
tobacco product0.533894
Tobacco Control0.618394
health0.488561
Low Machine-Measured Yields0.486658
regular cigarette0.682678
Certain redesigned cigarettes0.623296
Chronic Disease Prevention0.481608
ultralight cigarettes0.61529
extra cigarettes0.558295
tobacco industry documents0.585198
cigarette design0.541406
CLICK HERE
1413 National Cancer Institute Html en Delirium (PDQ®)–Patient Version Expert-reviewed information summary about delirium as a complication of cancer or its treatment. Supportive care and pharmacologic approaches to the management of delirium are discussed.
delirium symptoms0.709857
nitrogen waste products0.577723
PDQ cancer information0.770129
health care team0.586883
clinical trial search0.576381
white blood cells0.577889
clinical trials0.698332
health care providers0.640731
cancer information summary0.69366
health care professionals0.630449
clinical trial0.629959
family members0.626279
breast cancer prevention0.590247
risk factors0.581853
PDQ summaries0.586791
patients0.70258
cancer patients0.599627
latest published information0.583983
NCI’s PDQ0.59158
NCI PDQ cancer0.638613
medical conditions0.583938
mental state0.591128
treatment0.629672
medicines0.581999
cancer prevention0.590786
Cancer Information Service0.600573
PDQ Supportive0.581242
patient0.833691
treatment clinical trials0.58693
National Cancer Institute0.701492
PDQ documents0.58189
delirium0.950204
health care0.718989
Palliative Care Editorial0.637171
new treatment0.588734
Cancer Care page0.597168
PDQ database0.584618
patient changes0.579334
Care Editorial Board0.639637
risk factor0.616509
PDQ summary0.609325
cancer clinical trials0.602276
cancer information summaries0.605913
health professional versions0.578381
comprehensive cancer information0.605614
cancer patient0.595386
Older patients0.584199
cancer0.788674
CLICK HERE
1449 National Cancer Institute Html en Chronic Myelogenous Leukemia Treatment (PDQ®)–Health Professional Version Expert-reviewed information summary about the treatment of chronic myelogenous leukemia.
imatinib arm.0.510874
imatinib treatment0.498472
BCR/ABL tyrosine kinase.0.475402
chronic phase0.568994
selective imatinib intensification0.531551
chronic-phase CML0.475324
Kantarjian HM0.499766
standard-dose imatinib therapy0.507991
myeloid leukemia patients0.529265
optimized high-dose imatinib0.503652
imatinib dose escalation0.504714
chronic myeloid leukemia0.974854
myelogenous leukemia patients0.471866
first-line imatinib0.514414
newly diagnosed patients0.526185
CML0.506893
patients0.710768
imatinib0.732822
chronic myelogenous leukemia0.688539
molecular response0.621232
blast crisis0.504661
complete cytogenetic response0.48751
high-dose imatinib0.517116
previous tyrosine kinase0.510969
complete cytogenetic responses0.473533
tyrosine kinase inhibitor0.619296
BCR/ABL tyrosine kinase0.479945
et al.0.49902
Treatment-Naïve Chronic Myeloid0.474051
Imatinib plasma trough0.531841
tyrosine kinase0.812535
imatinib group0.503477
allogeneic bone marrow0.520192
newer tyrosine kinase0.511438
imatinib mesylate0.627198
Dasatinib Versus Imatinib0.532218
more-potent tyrosine kinase0.486098
bone marrow transplantation0.522565
tyrosine kinase inhibitors0.801096
10-year follow-up period0.488853
front-line imatinib0.512448
daily imatinib mesylate0.512872
major molecular response0.597118
Abstract0.523832
Clin Oncol0.565656
imatinib mesylate treatment0.521115
bone marrow0.522631
chronic myeloid leukaemia0.4741
imatinib era0.488593
CLICK HERE
1796 National Cancer Institute Html es Depresión (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del diagnóstico, evaluación y tratamiento de la depresión en adultos y niños que padecen de cáncer.
PDQ Adaptación0.900589
pequeño número0.729693
querido enfermo0.783448
siguientes aspectos0.842073
Physician Data Query0.803023
antidepresivos quizás0.773298
salud mental0.794578
suficiente apoyo0.736237
siguientes razones0.808967
sustancias químicas ayuda0.796554
Anfotericina B0.785281
médico hará preguntas0.761623
único irdn0.752807
Red Nacional0.736951
niños quizás0.74099
efectos tardíos0.735838
busque ayuda0.740646
National Cancer Institute0.721502
siguientes riesgos0.72378
siguientes pruebas0.814768
PDQ Depresión0.788745
siguientes temas0.821536
Instituto Nacional0.830302
CLICK HERE
1867 National Cancer Institute Html es Tratamiento del cáncer de seno paranasal y de cavidad nasal (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno paranasal y de cavidad nasal.
Lippincott Williams0.142692
Wynstra JH0.159843
Sterman BM0.185832
Neck Cancer Cooperative0.146574
Pilepich MV0.159353
Solero CL0.185478
seno etmoides0.29943
necesarias radioterapia0.151326
Pfister DG0.146109
malignant tumors0.232702
paranasal sinus0.195953
Arch Otolaryngol Head0.468056
Radiat Oncol Biol0.619431
DeVita VT Jr0.178945
Anterior craniofacial resection0.258045
Shah JP0.184681
Levine HL0.185883
Rosenberg SA0.139862
placas pterigoides0.137887
radiation therapy0.436289
Head Neck Surg0.553355
Factors influencing0.192749
Neck Tumors0.161157
Lawrence TS0.140398
Mendenhall WM0.145915
Head Neck0.837692
nasal vestibule0.268686
radioterapia postoperatoria0.19834
paranasal sinus tumors0.157406
radioterapia posoperatoria0.262078
Otolaryngol Head Neck0.541214
craniofacial resection0.26625
Mariani L0.182178
Cantù G0.181147
PDQ Tratamiento0.251079
Hawkins RB0.160122
9th ed0.144765
Kraus DH0.187503
nasal cavity0.24641
Werning JW0.146295
Oncol Biol Phys0.641171
cánceres nasofaríngeos0.195804
skull base0.209046
sección cáncer0.172955
Acta Otorhinolaryngol Belg0.258981
neck cancer0.879092
Acta Oncol0.146983
adjuvant radiotherapy0.160643
haz externo0.195232
CLICK HERE
1942 National Cancer Institute Html es Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica.
French-American-British Cooperative Leukaemia0.312371
leucemia mieloide0.341853
myelomonocytic leukaemia0.397359
myelomonocytic leukemia with0.326213
platelet-derived growth factor0.354049
with juvenile chronic0.315892
Arber DA0.312178
health organization classification0.3281
Leukemia Group0.315441
genes platelet-derived growth0.312347
with juvenile0.340061
chronic myeloid leukemia0.336615
myelomonocytic leukemia0.944712
leucemia mielomonocítica0.387953
chronic myelomonocytic leukemia0.819447
differentiating myelomonocytic leukemia0.320578
Beran M0.312167
World Health Organization0.355665
neoplasias mielodisplásicas0.314258
stem cell transplantation0.313202
chronic myelogenous leukemia0.364294
Germing U0.362762
myeloproliferative disorders0.313394
cases with chronic0.311538
Leuk Lymphoma0.332534
myelomonocytic leukemia from0.33992
chronic myelomonocytic leukaemia0.386185
juvenile chronic myelogenous0.347073
marrow transplantation0.341155
Organización Mundial0.317633
chronic myeloid0.357031
Differentiating juvenile myelomonocytic0.319715
myeloid neoplasms0.336696
bone marrow transplantation0.325127
Bennett JM0.319603
cromosoma filadelfia0.337822
recuento plaquetario0.325577
juvenile myelomonocytic leukaemia0.339361
juvenile myelomonocytic leukemia0.545157
chronic myeloid leukaemias0.320258
Clin Oncol0.32115
Orazi A0.343564
Cooperative Leukaemia Group0.311788
atypical chronic0.319445
características clínicas0.316309
trastornos mieloides0.311632
leucemia mieloide aguda0.316238
with chronic myelomonocytic0.340508
Emanuel PD0.350668
CLICK HERE
2004 National Cancer Institute Html es Familiares a cargo de pacientes de cáncer (PDQ®)–Versión para pacientes Sumario informativo revisado por expertos acerca de los desafíos que enfrentan los familiares a cargo de los pacientes con cáncer. Este resumen se centra en las funciones típicas y las inquietudes de las personas a cargo del paciente y en las intervenciones útiles para esas personas.
etapa final0.997354
medicamento ayuda0.410369
antecedentes médicos0.415405
duro trabajo0.413212
siguientes aspectos0.407494
siguientes tareas0.552864
PDQ Familiares0.404616
siguientes estrategias0.423753
largo plazo0.416925
orientación ayuda0.4088
siguientes riesgos0.402546
paciente ayuda0.564496
comunicación ayuda0.423969
Instituto Nacional0.414173
habilidades específicas mejora0.409415
paciente colabora0.698305
bienestar espiritual ayuda0.42734
Physician Data Query0.413876
siguientes recompensas0.416674
menudo personas0.450696
Medical Leave Act0.420162
escaso apoyo0.411288
Caregiver Cancer Education0.408929
numerosas tareas0.412096
PDQ Comunicación0.408163
terminales ayuda0.406412
largo tiempo0.456845
importantes decisiones0.42081
viejos problemas0.406452
CLICK HERE
2064 National Cancer Institute Html es Exposición al asbesto y el riesgo de cáncer Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información.
técnicos profesionales automotrices0.5421
gen bap10.530949
que familiares de trabajadores0.533144
normas descritas0.532666
largo plazo0.526581
Protección Ambiental0.672505
World Trade Center0.546459
principal dependencia0.532045
Ground Zero0.529197
derrames pleurales benignos0.558277
Salud Ocupacional0.584399
asbesto crisótilo0.987156
trabajadores portuarios0.606054
Instituto Nacional0.563708
menores riesgos0.533274
Trabajo de EE0.535904
Employment Standards Administration0.548898
titulado current best practices0.543841
Mine Safety0.535362
sustancias tóxicas0.635631
siglo xix0.53032
distintos tipos0.525229
Estados Unidos0.992615
automotriz usa0.531695
Public Affairs0.529764
serios problemas0.529441
Environmental Protection Agency0.815767
línea telefónica tsca0.556811
Preventing Asbestos Exposure0.544747
Product Safety Commission0.67091
Information Division0.52746
Occupational Safety0.586355
asbesto causa0.952053
cuánto tiempo0.527545
en la mucosidad0.531534
a las personas0.529484
posibles peligros0.5266
Health Administration0.652906
Consumer Product Safety0.672282
causa dificultad0.530297
sumamente bajo. Los fabricantes0.528798
mejores prácticas0.574094
Clutch Repair Workers0.544379
Veterans Affairs0.528386
Torres Gemelas0.52642
Compensation Programs0.5287
Disease Registry0.526245
Toxic Substances0.526971
Segunda Guerra Mundial0.550565
CLICK HERE
3457 National Cancer Institute Html es Aromaterapia y aceites esenciales (PDQ®)–Versión para pacientes Resumen de información revisada por expertos acerca del uso de la aromaterapia y los aceites esenciales para mejorar la calidad de vida de los pacientes de cáncer.
Aromaterapia Holística0.562365
células madre0.538543
Centro Nacional0.523442
cuidado médico0.513326
New Hampshire Avenue0.516719
Edad Media0.513057
Drug Administration0.51036
materiales básicos0.513447
NCI Best Case0.529134
Asociación Nacional0.510623
International Aromatherapists0.5134
datos bibliográficos pubmed0.517834
efectos calmantes0.525108
índices respiratorios0.51441
Canadian Federation0.513125
National Cancer Institute0.519273
aromaterapia mejora0.571233
siguientes riesgos0.511793
frecuencia respiratoria0.513664
Instituto Nacional0.589131
acupuntura ayuda0.509756
antigua china0.513893
Salud Complementaria0.537165
Visuals Online0.511883
complementarias revisa0.516354
Federación Canadiense0.511817
Physician Data Query0.568256
sistema nervioso central0.524289
verdaderos aceites0.552975
bacterias mrsa0.514519
Estados Unidos0.774616
francés rene gattefosse0.524782
libre uso0.513229
National Association0.51158
PDQ Aromaterapia0.574967
página manejo0.510182
¿El tratamiento0.520191
International Federation0.512341
¿Los beneficios0.51034
juntos cam0.50992
Holistic Aromatherapy0.51402
Series Program0.51015
medicina complementaria0.964619
CLICK HERE
3603 National Cancer Institute Html en The Biology of Cancer Health Disparities Melanie Nix is a triple-negative breast cancer survivor.
colorectal cancer driver0.435767
therapeutic drug development0.379727
higher prostate cancer0.449833
tumor suppressor0.38934
tumor suppressor protein0.381004
non-Ashkenazi Jewish women0.407407
health statistics data0.392619
poor prognosis0.391856
early-stage colorectal cancer0.438229
health disparities0.477585
white men0.458069
ethnic groups0.593764
higher death rate0.400926
5-year relative survival0.383397
E-cadherin-mediated cell–cell adhesion0.379902
prostate cancer cells0.46714
triple-negative breast cancer0.489042
Colorectal cancer incidence0.443522
colorectal cancer0.538585
health care services0.381316
prostate cancer risk0.477396
BRCA1 gene mutation0.382642
biological factors0.392157
tyrosine kinase activity0.387964
colorectal cancers0.435353
cancer health disparities0.462858
poor prognosis subtype0.390421
rare genetic variant0.379533
tyrosine kinase0.398457
African Americans0.45451
triple-negative disease0.382957
triple-negative breast cancers0.481447
poorer breast cancer0.423969
percent0.4497
African American men0.969659
African American patients0.426534
ephrin type-A receptor0.387324
premenopausal women0.412405
prognosis molecular subtype0.394461
germline BRCA1 mutations0.399431
African American women0.819019
breast cancer0.507647
prostate cancer growth0.440137
prostate cancer diagnosis0.440132
prostate cancer0.701352
non-Hispanic white women0.414153
aggressive prostate cancer0.430828
receptor tyrosine kinase0.392354
higher nuclear levels0.389163
CLICK HERE

 

 

 

Terms of Use | Privacy Policy
©2017 ARCHES Technology. All Rights Reserved.